Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Plataforma avanzada de diagnóstico molecular (DhITACT) para aplicaciones POC (diagnóstico inmediato)

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOKR20161006003
Publicado:
07/11/2016
Caducidad:
07/11/2017
Resumen:
Un laboratorio de biotecnología de una universidad de Corea del Sur ha desarrollado una plataforma de diagnóstico inmediato (POC) que se aplica para la detección temprana y prevención de enfermedades infecciosas, cáncer, metales pesados, toxinas, etc. El sistema es también una alternativa al análisis cuantitativo, como reacción en cadena de la polimerasa (PCR), inmunoensayo ligado a enzimas (ELISA), Western blot, etc., y ofrece una alta sensibilidad analítica con un tiempo de detección menor que el ofrecido por el análisis PCR con transcripción inversa convencional. La universidad busca socios con el fin de establecer acuerdos de comercialización, licencia e investigación.

Details

Tittle:
Advanced Molecular Diagnostic Platform Technology (DhITACT) For Point Of Care (POC) Applications
Summary:
A biotechnology lab at a university in South Korea has developed the point of care (POC) diagnostic platform technology. The technology can be applied to early detection and prevention of various infectious diseases. The university offers commercial and license agreement for the technology and research cooperation.
Description:
A university lab located in Seoul, South Korea has developed the point of care (POC) in vitro diagnostic platform technology. The lab belongs to the college of pharmacy and they are focusing on nano bio-material and nano technology in general. The research outcome has been covered by one of the most renowned academic journals on material engineering technology.

Every year, outbreaks of infectious diseases such as Ebola, MERS, and Zika virus have been reported worldwide. Therefore, the needs for rapid and simple in vitro diagnostic test have been growing quickly to prevent the subsequent secondary spread of the disease. Among different types of in vitro diagnosis, demand for molecular diagnosis is increasing due to its high sensitivity and selectivity. Within the molecular diagnosis, polymerase chain reaction (PCR)-based diagnosis is most widely utilized. However, PCR-based system always requires educated analysts and equipment, which are often too expensive for resource-limited environment in developing countries. Therefore, the lab has developed an innovative alternative diagnostic platform for PCR analysis, which is based on rolling circle amplification (RCA).

To be utilized as a field-friendly point of care (POC) diagnostic device, the lab has tried direct coupling of RCA products to the surface of microfluidic channels by primer immobilization and polymerization up on the detection of target pathogens. During the operation of the system, single-stranded (ss) RCA products are generated on the surface of microfluidic channels by an isothermal amplification process upon the selective binding of target nucleic acids from the biological fluids. As a result, the volume of the DNA hydrogel gradually enlarges during the incubation period, growing sufficiently large enough to block the channels. Thus, an operator can easily tell the presence of target pathogens by observing the blockage of flow in the microfluidic array chip. A complete blockage of flow in the micro channel is observed as well as the colorimetric optical detection after the addition of trypan blue solution. These changes are easily detectable by the naked eye without help of any additional equipment.

The system can be used as a point of care diagnosis while having molecular detection principal in field. This technology can be applied on biosensor for various targets such as infectious diseases, cancers, heavy metals, food toxins, and etc. In addition, the system can be an alternative technique for quantitative analysis such as Polymerase chain reaction (PCR), Enzyme linked immunoassay (ELISA), Western blot, and etc. With the full advantage of equipment-free operation at isothermal condition, the system offers highly comparable analytical sensitivity with considerably reduced detection time compared to the conventional reverse transcription (RT) PCR analysis. The system provides an accurate analysis result as compared to the conventional RT-PCR diagnosis.

The university lab offers commercial and license agreement and research cooperation agreement. The technology can be applied to infectious diseases diagnosis and prevention. Companies with expertise in healthcare, diagnosis can commercialise the technology and set their market to developing countries. The system does not require expensive devices or electrical power. The university lab and partner can cooperate for further development if it is required.
Advantages and Innovations:
1) easy and equipment free operation at isothermal condition to perform the diagnosis
2) simple optical detection of diagnostic results with the naked eye.
3) fast detection (within 15 min)
4) high sensitivity comparable to the conventional Polymerase chain reaction (PCR)
5) equipment free operation and detection with the naked eyes.

The technology is well matched to the industrial standpoint and prototypes are available for the demonstration.
Stage of Development:
Under development/lab tested
IPs:
Patents granted

Partner sought

Type and Role of Partner Sought:
- Type: companies with a lot of licensing experiences
- Activity: pharmaceuticals and healthcare
- Role: commercialise the product to market with licensing agreement.

The university lab expects partners can do such followings ´license out our technology´, ´commercialize our product´, ´co-develop and research to enhance the current technology´.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English

Keywords

Technology Keywords:
06001007 Medicina de urgencias
06001006 Vacunas humanas